

# Myrthe P P Van Herk-Sukel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7419876/publications.pdf>

Version: 2024-02-01

16  
papers

614  
citations

840119

11  
h-index

940134

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

1080  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2423-2429.	0.8	150
2	Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 843-851.	1.1	112
3	New opportunities for drug outcomes research in cancer patients: The linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. <i>European Journal of Cancer</i> , 2010, 46, 395-404.	1.3	110
4	Three-year dispensing patterns with long-acting inhaled drugs in COPD: A database analysis. <i>Respiratory Medicine</i> , 2011, 105, 259-265.	1.3	40
5	Aspirin Use After Diagnosis Improves Survival in Older Adults with Colon Cancer: A Retrospective Cohort Study. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 2232-2236.	1.3	36
6	Prescribing of Rosiglitazone and Pioglitazone Following Safety Signals. <i>Drug Safety</i> , 2012, 35, 471-480.	1.4	32
7	Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2012, 34, 238-244.	0.9	31
8	Record linkage for pharmacoepidemiological studies in cancer patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 94-103.	0.9	29
9	Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in the Netherlands. <i>Current Medical Research and Opinion</i> , 2009, 25, 195-204.	0.9	18
10	Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1036-1044.	0.9	17
11	COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 880-890.	0.9	11
12	Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel-proton pump inhibitor interaction. <i>Pharmacology Research and Perspectives</i> , 2016, 4, e00242.	1.1	10
13	Occurrence of Comorbidities before and after Soft Tissue Sarcoma Diagnosis. <i>Sarcoma</i> , 2012, 2012, 1-7.	0.7	8
14	Costs of hospital events in patients with metastatic colorectal cancer. <i>Journal of Medical Economics</i> , 2011, 14, 656-661.	1.0	6
15	Decrease in Switches to "Unsafe" Proton Pump Inhibitors After Communications About Interactions with Clopidogrel. <i>Clinical Drug Investigation</i> , 2017, 37, 787-794.	1.1	2
16	Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study. <i>Drugs - Real World Outcomes</i> , 2018, 5, 109-116.	0.7	2